Introduction
Allogeneic bone marrow transplantation (BMT) is a definitive curative therapy for the majority of hematological malignancies and severe immunodeficiencies. The major complication of allogeneic BMT remains graft-versus-host disease (GVHD) in which the skin, GI tract, liver and lung are preferentially damaged by the transplanted donor immune system. 1 GVHD occurs in the majority (50-70%) of recipients and is largely responsible for the high mortality associated with allogeneic BMT. Idiopathic pneumonia syndrome (IPS) is an acute non-infectious lung injury that typically occurs 3-4 weeks after BMT, responds poorly to therapy and is associated with a high mortality. 2 There is thus a pressing need for new treatment approaches to both prevent and treat the full spectrum of GVHD, based on a logical understanding of the underlying disease pathophysiology.
Current paradigms suggest that GVHD occurs via a complex cellular network initiated by the interaction of antigen presenting cells and naïve donor T cells. [3] [4] [5] Th1 differentiation leads to the generation of donor CTL and large amounts of inflammatory cytokines that damage host tissue by both MHC dependent and independent pathways. 6 Of the Th1 cytokines, IFNγ is perhaps the most immunologically dominant, influencing a plethora of cell subsets during allograft rejection. 7 However the effects of this cytokine on GVHD are unclear with a number of contradictory studies, [8] [9] [10] [11] suggesting that a clearer understanding of the mechanisms involved are needed. We have re-examined this issue using both IFNγ -/-and IFNγR -/-SCT donors or recipients following myeloablative conditioning. We demonstrate that donor-derived IFNγ indeed has both positive and negative effects on GVHD due to only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From differential effects on donor and host tissue, and individual target organs. Firstly, IFNγ augments acute GVHD via direct affects on the donor T cell to promote Th1 differentiation and the GI tract to augment inflammatory cytokine generation.
However, these detrimental effects are overwhelmed by a protective role of IFNγ in preventing the development of IPS and cutaneous GVHD. These studies provide additional mechanistic data that clarifies the conflicting studies to date and provides a logical system to identify a novel and previously unrecognized inhibitory pathway that prevents the development of IPS after SCT. mice and relevant control wild-type mice were supplied by The Australian National
University. The age of mice used as donors and recipients were between 7-10 weeks.
Mice were housed in sterilized microisolator cages and received acidified autoclaved water (pH 2.5) post-transplantation.
Cytokine mobilization. Recombinant human G-CSF (Amgen, Thousand Oaks, CA)
given subcutaneously at 10µg/animal days -6 to -1. Donor spleens were harvested on day 0.
Stem Cell Transplantation. Mice were transplanted as described previously. [12] [13] [14] Briefly, on day -1, B6D2F1 mice received 1100cGy total body irradiation or C57BL/6 and IFNγR -/-received 1000cGy total body irradiation (137Cs source at 108 cGy/min), split into two doses separated by 3 hours to minimise gastrointestinal toxicity. B6 (10 7 ) or Balb/c (2.5 x 10 7 ) donor splenocytes, corrected to administer equivalent numbers of CD3 + T cells (typically 40% of grafts) between groups, were injected intravenously on day 0. Animal procedures were undertaken using protocols approved by the institutional (QIMR) animal ethics committee. Transplanted mice were monitored daily and those with GVHD clinical scores ≥6 were sacrificed and the date of death registered as the next day in accordance with institutional animal ethics committee guidelines. We generated mixed chimeric mice by transplanting 5 x 10 6 wt only. Assessment of GVHD. The degree of systemic GVHD was assessed by scoring as previously described (maximum index = 10).
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Cell preparation. T cells were purified using magnetic bead depletion of non-T cell splenocytes. Briefly, following red cell lysis, splenocytes were incubated with purified mAb (CD19, B220, Gr-1, CD11b, Ter119). After incubation with antibodies, cells were incubated with goat anti-rat IgG BioMag beads (Qiagen Pty Ltd, Australia) for 20 minutes on ice, and then placed on a magnet. Subsequent CD3 + T cell purities were >90% and 2-3 x 10 6 T cells were added to T cell depleted grafts per animal. For total T cell depletion, splenocytes were incubated with hybridoma supernatants containing anti-CD4 (GK1.5), anti-CD8 (TIB211) and Thy1.2 (HO-13-4) monoclonal antibodies followed by incubation with rabbit complement (Cederlane Laboratories, ON, Canada) as previously described. 12 Note that this also eliminates professional antigen presenting cells which results in reduced GVHD severity. Cytokine and chemokine analysis. IFN-γ, IL-5, IL-4, IL-2 and TNF-α were determined using the BD Cytometric Bead Array system (BD Biosciences Pharmingen, San Diego, CA). All assays were performed according to the manufacturer's protocol. Chemokine ELISAs were conducted using antibodies and standards from R&D systems (Minneapolis, MN), as described previously. [18] [19] [20] Histology. Formalin preserved skin, liver, small bowel and lung were embedded in paraffin and 5-µm thick sections were stained with hematoxylin and eosin for histologic examination. Slides were coded and examined in a blinded fashion by A.D.C using the semi-quantitative scoring system as previously described. 12, 16, 17, 21 Scores were added to provide a total score of 24 for skin, 28 for small bowel, 
Results

Donor derived IFNγ protects against GVHD independent of effects on the donor graft.
To investigate the role of IFNγ in graft-versus-host disease, G-CSF mobilized IFNγ
IFNγR
-/-and wild-type (wt) grafts were transplanted into lethally irradiated allogeneic B6D2F1 recipients. Recipients of wt grafts died at a median of 27 days after transplant from GVHD. In contrast, recipients of IFNγ -/-grafts died significantly faster at a median of 14 days after transplant ( Fig. 1a) with clinical features of severe GVHD (Fig. 1b) . Recipients of T cell depleted (TCD) IFNγ -/-grafts survived the period of observation, demonstrating that the amplification of mortality in recipients of IFNγ -/-grafts was due to GVHD. Surprisingly, GVHD was significantly attenuated in recipients of allogeneic grafts which could not respond to IFNγ due to the deletion of the receptor ( Fig. 1a-b ). Importantly, this was not associated with any reduction in engraftment in these animals (99.9 ± 0.1% vs 99.8 ± 0.1% in recipients of WT vs IFNγR -/-grafts, peripheral blood at day 30). Thus, IFNγ produced by the donor graft has two independent and paradoxical effects. Firstly, in the complete absence of IFNγ generation, GVHD mortality is enhanced. Secondly, since the opposite occurs when there is no IFNγ signaling through the donor graft, we speculate that the protective effects of IFNγ are mediated through host tissue in a dominant fashion.
In order to understand the cause of rapid mortality of recipients of IFNγ -/-allografts we performed semi-quantitative pathology of GVHD target organs at day 14 after BMT. Surprisingly, these animals had developed severe interstitial pneumonitis characteristic of idiopathic pneumonia syndrome (IPS) ( (Fig. 4a-c) . This was an allogeneic phenomenon with all the features of IPS as it occurred in recipients of T cell replete but not T cell depleted allografts (Fig. 4a-b) . IFNγR -/-recipients of allogeneic grafts also had higher levels of cutaneous GVHD but surprisingly were protected from GVHD of the GI tract (Fig. 4a) . Thus the response of host tissue to IFNγ is a critical determinant of injury within individual GVHD target organs.
Donor T cells from IFNγR -/-recipients show a marked hyper-responsiveness to alloantigen.
We next studied the effect of IFNγ signaling through recipient tissue on donor T cell function. Nine days after transplant the absolute numbers of T cells, B cells and mononuclear cells in the spleen were not different between wt and IFNγR -/-recipients only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From (Fig. 5a ). Thus the previously demonstrated expansion of these cells in the lung was an organ specific phenomenon reflecting increased trafficking and/or expansion within the local lung environment. IFNγ levels within serum were raised in IFNγR -/-recipients compared to wt recipients but IL-5 levels were similar (Fig. 5b) .
Interestingly, despite the increased GVHD mortality, TNFα levels were decreased in the IFNγR -/-recipients, consistent with the low levels of GVHD in the GI tract. Donor CD4 and CD8 T cells were next sort purified from wt or IFNγR -/-recipients nine days after transplant and re-stimulated with host DC or used as effectors in chromium assays. As shown in Fig. 5c , donor CD4 T cells from IFNγR -/-recipients displayed hyper-responsiveness to alloantigen with marked increases in cytokine production while donor CD8 T cells displayed increased cytotoxicity against host-type targets (Fig. 5d) . Thus the inability of host tissue to respond to IFNγ results in heightened donor T cell effector responses, confirming that IFNγ acts to suppress donor T cell responses during GVHD via effects on host tissue.
IFNγ signaling through non-haematopoietic cells controls GVHD target tissue injury.
Donor derived IFNγ could conceivably be acting at two host sites to modulate GVHD.
First, it may act on host APC early after SCT to, in this case, inhibit their stimulatory capacity and reduce donor T cell effector function. Secondly, IFNγ may act on GVHD target tissue to provide direct protection from pulmonary GVHD or induction of GVHD of the GI tract respectively. To dissect the level at which modulation of GVHD was occurring, we generated mixed bone marrow chimeras in which wt or IFNγR -/-bone marrow was transplanted into either wt or IFNγR -/-recipient mice as described in materials and methods. Three months later we undertook flow cytometric analysis to study the turn over of antigen presenting cells (macrophages and DC) in only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From the lung in these chimeras. As shown in Fig. 6a , pulmonary macrophages and dendritic cells were of donor origin (CD45.2 + ) in these chimeras. Thus we could indeed use these animals as secondary transplant recipients to dissect the role of the IFNγR on host lung APC versus lung parenchymal tissue in the development of IPS.
When these mixed chimeras were used as recipients, histological analysis nine days after transplant (Fig. 6b-c 
IFNγ-dependent protection from IPS is not via the nitric oxide or indoleamine 2,3 dioxygenase pathways.
IFNγ may conceivably be acting on lung parenchymal tissue to prevent IPS by inducing the secretion of immunosuppressive molecules and/or inhibiting donor cell migration across pulmonary endothelium into the lung. A recent study demonstrated that endogenous nitric oxide (NO) inhibits the development IPS 23 and this molecule is also known to be an IFNγ-dependent negative regulator of T cell function. We therefore determined inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) mRNA transcript levels within lung tissue using real-time PCR analysis. Surprisingly, these studies demonstrated slightly increased iNOS and eNOS in the lung of IFNγR -/-compared to wt recipients, the opposite to that which would be expected if these molecules were providing IFNγ-dependent inhibition of only.
For (Fig. 7a) . Since these PCR results may reflect levels of iNOS and eNOS in infiltrating donor cells rather than recipient lung parenchyma, we also utilized iNOS -/-and eNOS -/-mice as SCT recipients. These knock out mice failed to develop any features of IPS, as would have been expected if the generation of NO from host tissue in response to IFNγ was preventing the development of IPS in wt recipients (Fig. 7b) . We next investigated indoleamine-2,3-dioxygenase (IDO) as an alternative IFNγ-dependent inhibitory pathway. IDO is also capable of inhibiting T cell proliferation 24 and has an inhibitory role in the rejection of lung allografts. 
IFNγ inhibits donor cell migration into the lung and subsequent expansion.
We next examined whether IFNγ was controlling leukocyte adhesion and/or migration into the lung. As shown in Fig. 7c and d Fig 1b) although the full significance of this will require studies based on functional inhibition of VCAM-1 and/or VLA-4. In contrast, ICAM was highly expressed throughout lung without any differences between groups evident (data not shown). Interestingly, mRNA levels of heme oxygenase-1 were also elevated in IFNγR -/-recipients ( supplementary Fig 1c) , consistent with a response to the lung injury evident in these animals. 29, 30 We were unable to detect consistent increases in chemokines known to influence IPS, including those controlled by IFNγ, [31] [32] [33] [34] 
Discussion
IFNγ has been attributed with both pathogenic and protective effects in transplant medicine although clear mechanisms to explain this paradox have not been defined.
By utilizing receptor deficient mice we demonstrate here that IFNγ indeed has direct pathogenic effects on donor T cells to promote Th1 differentiation and the gastrointestinal parenchyma to directly promote GVHD. However, these effects are overwhelmed by protective effects mediated through the lung parenchyma to prevent the development of fulminant IPS. It should be noted that G-CSF mobilized grafts were utilized in these studies to reflect the majority of current clinical practise.
However IPS also developed in an equivalent fashion in IFNγR -/-recipients of traditional bone marrow grafts supplemented with splenic T cells (data not shown).
Initial studies using IFNγ -/-donor mice in non-irradiated recipients demonstrated a delay in GVHD mortality in the absence of this cytokine associated with Th2 differentiation 8, 35 and impairment of Fas dependent CTL function. 9 Conversely, subsequent studies utilizing irradiated recipient mice demonstrated enhanced acute GVHD following transplantation of IFNγ -/-grafts or IFNγ -/-neutralization 10,11 and protection following the administration of IFNγ after BMT. 36 This effect was associated with enhanced in vitro proliferation and IL-2 generation from donor T cells to alloantigen. 11 Interestingly, IFNγ was subsequently shown to inhibit the capacity of donor CD8 T cells to expand after BMT and induce GVHD but GVL effects were paradoxically enhanced. 11 Together, this data confirmed the now established principle that BMT conditioning has important effects on the incidence and severity of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From GVHD 16, 37 and that CD4 and CD8 T cell effects may be differentially regulated after BMT. 38 With the benefit of simultaneous data generated using both IFNγ -/-and IFNγR -/-mice we have now established the mechanism of action of this cytokine in GVHD pathogenesis which have yielded highly surprising and novel results. Importantly, the proposed concept that IFNγ inhibits GVHD by inhibition of donor T cell function inferred from previous studies is not consistent with the data gained when IFNγR The demonstration here that the protective/suppressive effects of IFNγ are instead all mediated through recipient tissue was unexpected. The differential effects of this cytokine on the incidence of GVHD within specific target organs was also surprising and clearly demonstrated that the rapid mortality in recipients lacking IFNγ signaling was due to the development of severe IPS in association with enhanced cutaneous GVHD. Given that IPS has previously been causally linked to pro-inflammatory The GI tract is known to be highly sensitive to damage by TNFα, 37 and so the finding of low levels of GVHD in the GI tract of IFNγR -/-recipients in association with only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From reduced levels of TNFα is perhaps not surprising. However, it has been previously proposed that the role of IFNγ in this pathway was to prime monocytes and macrophages so that they secrete pathogenic quantities of TNFα following LPS stimulation. 22, 37 Surprisingly, the studies here demonstrate that priming by IFNγ occurs predominantly via cells of host origin since TNFα levels were reduced when the host but not the donor lacked the IFNγR (Fig. 5b and 2d) . However, the pathogenic effect of IFNγ on GVHD of the GI tract was not mediated through host macrophages, or indeed any other cell of hematopoietic origin since GI tract injury occurred only when the GI tract parenchyma itself lacked the IFNγR. The effects of IFNγ on the GI tract have been described, and primarily include crypt hypertrophy and villous atrophy. 48, 49 This study supports the notion that these direct effects are central to the primary pathogenesis of gut GVHD induced by IFNγ. 
